Replies to post #37051 on $heff's $tation of $tocks & $olid DD

[ronpopeil]

good job barefoot. as long as you make a profit, you should be happy. i think 2011 will be a great year for DCTH. also, hoping for good things for DEPO and AMRN. picked up some AIS earlier too.

[ronpopeil]

The Wedbush & Morgan analyst maintained his rating on the shares of (DCTH) and his ---> $21.00 dollar a share price target.
----------------------------------------------------------------------


Wedbush & Morgan : EQUITY RESEARCH
Analyst: Gregory R. Wade, Ph.D.

December 22, 2010


Delcath Systems, Inc. (DCTH - OUTPERFORM):
Price Target: $21.00
Delcath Completes / FDA FILING w/ Submission to the FDA*

Price: $10.73 (intraday 12/22/10)

As anticipated Delcath announced the completion of their NDA
submission to the FDA for their PHP chemosaturation system.

The Company has requested priority review of their NDA which could facilitate
a 6 month review of the application and Q2:11 PDUFA date. Announcement about
priority or regular review and PDUFA date from the FDA is expected within 60 days.

We remain confident that the PHP system will receive FDA approval based upon
the highly statistical and compelling achievement of success at the endpoint
pre-specified in the Special Protocol Agreement.

We anticipate a PDUFA date for the PHP system in mid:11 should
priority review be granted and YE:11 if not.* Management is confident that
the NDA will get priority review. Potential FDA advisory panel meetings for
the Delcath NDA include the Oncology Drugs Advisory Committee meeting on
June 28-29, July 13-14, September 14-15, or December 7-8.


DCTH intends to submit the PHP Phase III data to a journal for
publication in Q4:10, which could allow for publication of results in
Q1:11.

The paper is expected to include additional subgroup analyses
permitted by the Phase III statistical rules.

Asian partnering discussions are progressing, however, management
would not provide a target date for completing a deal. * Management stated
that discussions are proceeding with multiple parties for potential rights
in China, Korea and/or Japan. The company reported that primary interest of
Asian partners has been the HCC setting with doxorubicin as the
chemotherapeutic agent.

On December 6th the Company applied for a Class 3 CE marking in Europe
with potential approval expected in mid:11.* Additional near-term
milestones for the Company include the completion of GMP audit.

DCTH ended the third quarter with approximately $54.3 million in cash
and is currently burning approximately $2.2 million/month. * The burn rate
is expected to increase towards the end of the year as the company prepares
for the future US PHP sales team.

Maintain our OUTPERFORM rating and our $21/share fair value.
Our $21 fair value is derived from 5x (historical multiple for a novel device
product) our 2015 sales estimate ($506 million) discounted back 5.5 years at
20% per year, and includes the effect of the exercise of the 3.8 million
warrants outstanding and an increase in the share count by 5 million shares
for a future potential financing. Upside to these expectations could come
from more off-label utilization than we are presently modeling.

[ronpopeil]

ROTH CAPITAL REPORT -----> Roth Capital Maintans DCTH ..&... $16.50 Price Target
ROTH CAPITAL PARTNERS
December 22, 2010

============================================
Delcath Systems Inc. ---- DCTH - NASDAQ
Buy Rated --- $16.50 Target
============================================

Prev Close: $10.81
Price Target: $16.50
Market Cap: $463 Million

DCTH: Sends NDA Package to FDA Just in Time; Buy This morning, Delcath announced that it submitted the final modules of its
505(b)(2) NDA (New Drug Application) for its chemosaturation system (known as the PHP system in its pivotal study and branded the Delcath
Hepatic ChemoSAT Delivery System in the EU) to the FDA. This announcement comes in right on time with our expectations for a filing
before the end of the year.

* Of note, Delcath filed for priority review, which would result in a
six month review period if granted by FDA. As a result, the company
remains on track to obtain potential US FDA approval, as well as CE Mark,
around the middle of 2011.

* The FDA performs a 60-day review to determine if a NDA warrants a
thorough review and will (1) assign its review period as well as (2)
establish a PDUFA (Prescription Drug User Fee Act) date at that time.
We see these events as the next predictable catalysts for the company.

* Additionally, we continue to expect that following its NDA submission,
DCTH will likely release the top-line data from its Phase II multi-arm trial to treat
other liver cancers.

* Delcath has continued to hit its key milestones as it moves the
ChemoSAT system through its respective regulatory processes, which we view as a
positive sign for management's ability to execute. Entering 2011, much
of the company's prospects sit in the hands of the FDA, which can be much
less predictable than the filing process, but we believe the data
package assembled by Delcath offers a strong probability of success next year.

* We maintain our Buy rating on DCTH .....and..... $16.50 Price Target